Press Resease

Hepatitis C Drug Market - Global Industry Analysis

Hepatitis C Drug Market by End-User (Hospitals, Private labs, Physician offices, Public health labs, and Blood Bank): Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 – 2028

Published Date: 26-Jul-2021 Category: Pharmaceutical Report Format : PDF Pages: 150 Report Code: ZMR-1326 Status : Published

The global Hepatitis C Drug market accounted for USD 20.5 Billion in 2020 and is expected to reach USD 69.1 Billion by 2028, growing at a CAGR of around 16.3% between 2021 and 2028.

Description

Market Overview                        

The global Hepatitis C Drug market accounted for USD 20.5 Billion in 2020 and is expected to reach USD 69.1 Billion by 2028, growing at a CAGR of around 16.3% between 2021 and 2028.    

Hepatitis is inflammation of the liver characterized by yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomitingheadaches, poor appetite, joint pain, and clay colored stools.

Hepatitis C is a significant public health concern that affected more than 400.2 Million patients globally in 2019. Even more alarming, only 0.4 Million were treated per year, showing the need for increased screening and timely diagnosis.

The partnerships and mergers and acquisitions of players in the Hepatitis C Drug market is also set to propel the market growth. For example, in April 2019, U.S. FDA announced the approval of Mavyret by AbbVie for the first ever treatment approved for pediatric patients of all genotypes of hepatitis C.

COVID-19 Impact Analysis:

The lockdowns imposed by various countries to contain the spread of Covid-19 has impacted the global operations and supply chain which had a negative consequences on Hepatitis C Drug market as the global sales declined. As healthcare professionals increasingly direct their resources towards caring for coronavirus-infected patients, other health issues are being relegated to the back seat. The players in the industry have temporarily suspended the production of Hepatitis C Drug in order to cater corona virus patients.

The significant decrease in the global Hepatitis C Drug market size in 2020 is estimated on the basis of the COVID-19 outbreak and its negative impact on the economies and industries across the globe. Various scenarios have been analyzed on the basis of inputs from various secondary sources and the current data available about the situation.   

Growth Factors

The global hepatitis C drug market was likely to see development in the near future owing to increase in the occurrence of HCV all over the world. In addition to this, lack of awareness is believed as a major fostering factor that promotes the growth of hepatitis C drug market. Moreover, many lifestyle-associated factors, such as transferring of body fluid, unsafe sex, and having multiple sex partners are likely to propel the development of hepatitis C drug market. On the other hand, lack of information and awareness about HCV, threat-related to development & regulation of drug, and treatment cost might hinder development of hepatitis C drug market.

Nevertheless, new efficient treatments are likely to bring growth opportunities in hepatitis C market in the foreseeable future. For example, in April 2018, a nonprofit organization made new hepatitis C medication that is just as effective as those made by other drug giants. This is supposed to bolster the development of hepatitis C drug market.

Report Scope:  

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Segment Analysis Preview  

The hepatitis C drug market is divided based on end-users into five types such as private labs, hospitals, public health labs, physician offices, and blood banks. These sectors are the major end-users of global hepatitis C drug market. In terms of income, hospitals were the dominating end-user recently and the same is anticipated to be the fastest and biggest developing sector in the hepatitis C drug market during the forecast period.

Regional Preview:

North America was the dominating market for hepatitis C drug market in terms of income owing to the broad accessibility of hospitals. Moreover, lifestyle-associated factors such as unprotected sex and having multiple sex partners have become very ordinary in European nations and North America. Furthermore, hepatitis C drug has huge growth avenues in emerging regions such as Latin America and Asia Pacific due to the government initiatives, rising number of patient suffering from HCV, and healthcare infrastructure.

Key Market Players & Competitive Landscape

The major players operating Hepatitis C Drug market are Merck & Co, Kenilworth, Roche, Basel GlaxoSmith, Gilead Sciences, AbbVie, Johnson & Johnson and Bristol-Myers Squibb.

The global Hepatitis C Drug market is segmented as follows:  

By End-User

  • Hospitals
  • Private labs
  • Physician offices
  • Public health labs
  • Blood Bank

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter No. 1: Introduction
    • 1.1. Report Description
      • 1.1.1. Purpose of the Report
      • 1.1.2. USP & Key Offerings
    • 1.2. Key Benefits for Stakehulders
    • 1.3. Target Audience
    • 1.4. Report Scope
  • Chapter No. 2: Executive Summary
    • 2.1. Key Findings
      • 2.1.1. Top Investment Pockets
        • 2.1.1.1. Market Attractiveness Analysis, By End-User
        • 2.1.1.2. Market Attractiveness Analysis, By Region
    • 2.2. Market Snapshot
    • 2.3. Global Hepatitis C Drug Market, 2016 – 2028 (USD Billion)
    • 2.4. Insights from Primary Respondents
  • Chapter No. 3: COVID 19 Impact Analysis
    • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
      • 3.1.1. North America
      • 3.1.2. Europe
      • 3.1.3. Asia Pacific
      • 3.1.4. Latin America
      • 3.1.5. The Middle-East and Africa
    • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
    • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion)
    • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion)
    • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
      • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
    • 3.6. Short Term Dynamics
    • 3.7. Long Term Dynamics
  • Chapter No. 4: Hepatitis C Drug Market – End-User Segment Analysis
    • 4.1. Overview
      • 4.1.1. Market Revenue Share, By End-User, 2020 & 2028
    • 4.2. Hospitals
      • 4.2.1. Market Size and Forecast, By Region (USD Billion)
      • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.3. Private labs
      • 4.3.1. Market Size and Forecast, By Region (USD Billion)
      • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.4. Physician offices
      • 4.4.1. Market Size and Forecast, By Region (USD Billion)
      • 4.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.4.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.5. Public health labs
      • 4.5.1. Market Size and Forecast, By Region (USD Billion)
      • 4.5.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.5.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.6. Blood Bank
      • 4.6.1. Market Size and Forecast, By Region (USD Billion)
      • 4.6.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.6.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.1. Overview
      • 5.1.1. Global Market Revenue Share, By Region, 2020 & 2028
      • 5.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Billion)
    • 5.2. North America
      • 5.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 5.2.2. North America Market Revenue, By End-User, 2016 – 2028
      • 5.2.5. U.S.
        • 5.2.5.1. U.S. Market Revenue, By End-User, 2016 – 2028
      • 5.2.6. Canada
        • 5.2.6.1. Canada Market Revenue, By End-User, 2016 – 2028
      • 5.2.7. Mexico
        • 5.2.7.1. Mexico Market Revenue, By End-User, 2016 – 2028
    • 5.3. Europe
      • 5.3.1. Europe Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 5.3.2. Europe Market Revenue, By End-User, 2016 – 2028
      • 5.3.5. Germany
        • 5.3.5.1. Germany Market Revenue, By End-User, 2016 – 2028
      • 5.3.6. France
        • 5.3.6.1. France Market Revenue, By End-User, 2016 – 2028
      • 5.3.7. U.K.
        • 5.3.7.1. U.K. Market Revenue, By End-User, 2016 – 2028
      • 5.3.8. Italy
        • 5.3.8.1. Italy Market Revenue, By End-User, 2016 – 2028
      • 5.3.9. Spain
        • 5.3.9.1. Spain Market Revenue, By End-User, 2016 – 2028
      • 5.3.10. Rest of Europe
        • 5.3.10.1. Rest of Europe Market Revenue, By End-User, 2016 – 2028
    • 5.4. Asia Pacific
      • 5.4.1. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 5.4.2. Asia Pacific Market Revenue, By End-User, 2016 – 2028
      • 5.4.5. China
        • 5.4.5.1. China Market Revenue, By End-User, 2016 – 2028
      • 5.4.6. Japan
        • 5.4.6.1. Japan Market Revenue, By End-User, 2016 – 2028
      • 5.4.7. India
        • 5.4.7.1. India Market Revenue, By End-User, 2016 – 2028
      • 5.4.8. South Korea
        • 5.4.8.1. South Korea Market Revenue, By End-User, 2016 – 2028
      • 5.4.9. South-East Asia
        • 5.4.9.1. South-East Asia Market Revenue, By End-User, 2016 – 2028
      • 5.4.10. Rest of Asia Pacific
        • 5.4.10.1. Rest of Asia Pacific Market Revenue, By End-User, 2016 – 2028
    • 5.5. Latin America
      • 5.5.1. Latin America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 5.5.2. Latin America Market Revenue, By End-User, 2016 – 2028
      • 5.5.5. Brazil
        • 5.5.5.1. Brazil Market Revenue, By End-User, 2016 – 2028
      • 5.5.6. Argentina
        • 5.5.6.1. Argentina Market Revenue, By End-User, 2016 – 2028
      • 5.5.7. Rest of Latin America
        • 5.5.7.2. Rest of Latin America Market Revenue, By End-User, 2016 – 20285
    • 5.6. The Middle-East and Africa
      • 5.6.1. The Middle-East and Africa Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 5.6.2. The Middle-East and Africa Market Revenue, By End-User, 2016 – 2028
      • 5.6.5. GCC Countries
        • 5.6.5.1. GCC Countries Market Revenue, By End-User, 2016 – 2028
      • 5.6.6. South Africa
        • 5.6.6.1. South Africa Market Revenue, By End-User, 2016 – 2028
      • 5.6.7. Rest of Middle-East Africa
        • 5.6.7.1. Rest of Middle-East Africa Market Revenue, By End-User, 2016 – 2028
  • Chapter No. 6: Hepatitis C Drug Market – Industry Analysis
    • 6.1. Introduction
    • 6.2. Market Drivers
      • 6.2.1. Driving Factor 1 Analysis
      • 6.2.2. Driving Factor 2 Analysis
    • 6.3. Market Restraints
      • 6.3.1. Restraining Factor Analysis
    • 6.4. Market Opportunities
      • 6.4.1. Market Opportunity Analysis
    • 6.5. Porter’s Five Forces Analysis
    • 6.6. PEST Analysis
    • 6.7. Regulatory Landscape
    • 6.8. Technulogy Landscape
    • 6.9. Regional Market Trends
      • 6.9.1. North America
      • 6.9.2. Europe
      • 6.9.3. Asia Pacific
      • 6.9.4. Latin America
      • 6.9.5. The Middle-East and Africa
    • 6.10. Pricing Analysis
    • 6.11. Value Chain Analysis
    • 6.12. Downstream Buyers
    • 6.13. Distributors/Traders List
  • Chapter No. 7: Competitive Landscape
    • 7.1. Company Market Share Analysis – 2019
      • 7.1.1. Global Hepatitis C Drug Market: Company Market Share, 2019
      • 7.1.2. Global Hepatitis C Drug Market, Company Market Revenue, 2016 – 2019 (USD Billion)
      • 7.1.3. Global Hepatitis C Drug Market, Company Y-o-Y Growth, 2017 – 2028 (%)
      • 7.1.4. Global Hepatitis C Drug Market: Radar Determinant Chart, 2019
    • 7.2. Strategic Developments
      • 7.2.1. Acquisitions & Mergers
      • 7.2.2. New Product Launch
      • 7.2.3. Regional Expansion
    • 7.3. Company Strategic Developments – Heat Map Analysis
  • Chapter No. 8: Company Profiles
    • 8.1. Merck & Co
      • 8.1.1. Company Overview
      • 8.1.2. Key Executives
      • 8.1.3. Product Portfulio
      • 8.1.4. Financial Overview
      • 8.1.5. Operating Business Segments
      • 8.1.6. Business Performance
      • 8.1.7. Recent Developments
    • 8.2. Kenilworth
    • 8.3. Roche
    • 8.4. Basel GlaxoSmith
    • 8.5. Gilead Sciences
    • 8.6. AbbVie
    • 8.7. Johnson & Johnson
    • 8.8. Bristul-Myers Squibb
  • Chapter No. 9: Marketing Strategy Analysis
    • 9.1. Marketing Channel
    • 9.2. Direct Marketing
    • 9.3. Indirect Marketing
    • 9.4. Marketing Channel Development Trends
    • 9.5. Economic/Pulitical Environmental Change
  • Chapter No. 10: Research Methodulogy
    • 10.1. Research Methodulogy
    • 10.2. Phase I - Secondary Research
    • 10.3. Phase II - Data Modeling
      • 10.3.1. Company Share Analysis Model
      • 10.3.2. Revenue Based Modeling
    • 10.4. Phase III - Primary Research
    • 10.5. Research Limitations
      • 10.5.1. Assumptions

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Hepatitis C Drug market. Zion Research has collected and analyzed key data belong to the global Hepatitis C Drug market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account, while estimating market size. The revenue generated by the leading industry participants in from the sales of Hepatitis C Drug across the world has been calculated through primary and secondary research.

Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in validation of findings from secondary research and to understand key trends in the Hepatitis C Drug industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further, develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Hepatitis C Drug market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Free Analysis

Hepatitis C is a serious liver disease that is caused as a result of infection with the hepatitis C virus. From a long time, hepatitis C has been called a silent disease because people can get infected and not know it for years. Some people who get infected with hepatitis C virus are able to clear or get rid of the virus, but most people who get infected develop a chronic, or lifelong, infection. Over time, chronic hepatitis C can cause serious health problems including liver damage, liver failure, and even liver cancer.

Globally, hepatitis C drug market has been accelerated due to the continuous rise in the percentage of hepatitis C infections among individuals. Furthermore, lack of awareness is considered as a major key factor which is expected to promote the growth of hepatitis C drug market. Moreover, many lifestyle-related factors, such as unprotected sex, unhygienic precautions by the medical institution can also promote the hepatitis C infection. In addition, rising government funding coupled with a smaller period of treatment are likely to fuel the growth of hepatitis C drug market.  However, the high cost of drugs coupled with threat-related to regulation and development of the drug is a key restraining factor for the growth of hepatitis C drug market. Nonetheless, ongoing research and upcoming new efficient therapies are expected to bring growth avenues in nearby future.

On the basis of end-users, hepatitis C drug market is segmented into five types: hospitals, private labs, physician offices, public health labs and blood banks. These segments are the key end-users of hepatitis C drug market. Among all, hospital and labs are the major segments and are expected to be the fastest growing applications in forthcoming years.

On the basis of geographical regions, the global hepatitis C drug market is segmented into five regions which include North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. These regions are further sub-segmented into the U.S., U.K., Germany, France, China, Japan, India, and Brazil. North America was the largest regional market for hepatitis C drugs in 2016. In this region, the U.S. was the largest revenue contributor for global hepatitis C drug market. Further, it is expected to continue this trend during near future owing to ongoing research and development in pharmaceutical industry. Europe was the second largest market for hepatitis C drugs. Further, demand for hepatitis C drug is increasing in Asia-Pacific, Latin America and Middle East & Africa region due to the prevalence of the disease in these regions coupled with increasing expenditure on healthcare infrastructure over the years to come.

Major key players in the global hepatitis C drug market includes Merck & Co, Kenilworth, Roche, Basel GlaxoSmith, Gilead Sciences, AbbVie, Johnson & Johnson and Bristol-Myers Squibb.


Frequently Asked Questions

The global Hepatitis C Drug Market was valued at USD 20.5 Billion in 2020.

The global Hepatitis C Drug Market is expected to reach USD 69.1 Billion by 2028, growing at a CAGR of 16.3% between 2021 to 2028.

Some of the key factors driving the global Hepatitis C Drug Market growth are lifestyle-associated factors, such as transferring of body fluid, unsafe sex, and having multiple sex partners.

North America was the dominating market for hepatitis C drug market in terms of income owing to the broad accessibility of hospitals. Moreover, lifestyle-associated factors such as unprotected sex and having multiple sex partners have become very ordinary in European nations and North America.

Some of the major players of global Hepatitis C Drug market are Merck & Co, Kenilworth, Roche, Basel GlaxoSmith, Gilead Sciences, AbbVie, Johnson & Johnson and Bristol-Myers Squibb.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Are On Social